Brief: Hillevax Reports Full Year 2022 Financial Results And Highlights Recent Company Progress
17/03/2023 20:10
March 17 (Reuters) - Hillevax Inc HLVX.O :
* HILLEVAX REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND
HIGHLIGHTS
RECENT COMPANY PROGRESS
* SEES TOPLINE SAFETY AND CLINICAL EFFICACY DATA FROM
NEST-IN1 IN
Q1 OF 2024
* AS OF DECEMBER 31, 2022, COMPANY HAD CASH AND CASH
EQUIVALENTS
TOTALING $279.4 MILLION
* QTRLY LOSS PER SHARE $0.56
* Q4 EARNINGS PER SHARE VIEW $-1.46 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNXbw6LyC
Further company coverage: HLVX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HilleVax
See all newsBrief: XOMA Royalty Announces Closing Of Tender Offer For HilleVax
Brief: Hillevax Enters Into A Definitive Agreement To Be Acquired By Xoma Royalty For $1.95 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
U.S. STOCKS ON THE MOVE-Zumiez, BTC Digital, WesBanco
U.S. STOCKS ON THE MOVE-Petco Health, Smith & Wesson, Victoria's Secret